According to the company, the new product is shipped as a flow-through and will be available at all existing retailers, including major drugstores CVS, Walgreens and Rite-Aid, mass
Initially, the company aims to develop and manufacture hemp and THC-free formulations that create medicinal compounds that don’t produce the ‘high’ associated with cannabis containing THC. Scientific research
Aspyrian has received an exclusive license from the National Cancer Institute for a new ADC technology platform, Near-infrared Photoimmunotherapy (PIT), which is expected to offer highly efficient and
Pursuant to the terms of the agreement, AMRI will acquire all the outstanding shares of Cedarburg Pharmaceuticals for $38.2m in cash. The transaction, including $2.8m of assumed liabilities,
The company said that the new use is for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. So far, H1-antihistamines have
Lemtrada is supported by a clinical development program that involved about 1,500 patients and 5,400 patient-years of follow-up. The approval in Brazil follows the recent approvals of Lemtrada
The company said that if approved, empagliflozin will be marketed under the name Jardiance. Empagliflozin belongs to the SGLT2 inhibitor class of drugs that targets glucose directly and
The decision to return the rights of tozadenant has been made on the assessment of UCB’s early and late stage clinical development pipeline as well as its preclinical
The European Medicines Agency’s (EMA) CHMP has issued positive opinions for the conditional marketing authorizations of Vynfinit, Folcepri and Neocepri to treat adult patients with folate receptor-positive, platinum-resistant,
The drug is indicated for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn’s disease (CD) who
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.